Course Description
Substance use disorders and co-occurring eating disorders (ED) may be overlooked. A past CPNP presentation on eating disorders cited 10 to 25% of patients with ED have a co-occurring SUD. SAMHSA reports a National Comorbidity survey of almost 3000 patients in 2011 that cited rates of any SUD ranging from 23 to 36.8% across all three eating disorders. Some references cite as high as high as 50% of individuals with ED have misused alcohol or illicit drugs, which is 5 times higher than the general population. For those pharmacists practicing in the SUD space Up to 35% of individuals who abused or were dependent on alcohol or other drugs have also had eating disorders, a rate 11 times greater than the general population.
The substances most frequently misused by individuals with eating disorders or with sub-clinical symptoms include alcohol, laxatives, emetics, diuretics, amphetamines, heroin, and cocaine. Eating disorders and substance use disorders share a number of common risk factors, including brain chemistry, family history, low self-esteem, depression, anxiety, and social pressures. Other shared characteristics include compulsive behavior, social isolation, and risk for suicide.
Learning Objectives
- Illustrate the prevalence and overlapping risk factors for co-occurring substance use disorders and eating disorders.
- Categorize the risks of substances most frequently misused in persons with eating disorder.
- Choose treatment strategies (non-pharmacologic and pharmacotherapy) for a patient with eating disorder and substance use disorder.
Target Audience
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
Faculty
View biographical information
Danielle Stutzman, PharmD, BCPP
Assistant Adjoint Professor, Psychiatry-Child-CHC,
School of Medicine, University of Colorado
Clinical Pharmacist-Psychiatry
Children’s Hospital Colorado
Aurora, CO
Danielle Stutzman, PharmD, BCPP, is a Clinical Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and serves as a Psychiatric Pharmacist at the Pediatric Mental Health Institute at Children’s Hospital Colorado. Dr. Stutzman serves as an integral member of inpatient, partial hospitalization, and outpatient child and adolescent psychiatry treatment teams to ensure optimal use of psychotropic medications among youth and leads medication education groups for adolescents and caregivers. She provides formal lectures for child and adolescent psychiatry fellows, developmental pediatrics fellows, pharmacy students, and serves as a training preceptor for pharmacy students and residents.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 10/07/2022
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-22-077-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Planning Committee
|
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid), Wolters-Kluwer, paid consultant |
|
Cassandra Davis, PharmD, BCPP, BCPS Mental Health Clinical Pharmacy Specialist Orlando VA Medical Center Orlando, FL No Relevant Financial Relationships to Disclose |
 Megan J. Ehret, PharmD, BCPP, MSBCPP Program Director Professor University of Maryland Baltimore, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
 Sarah Melton, PharmD, BCPP, BCACP, FASCPChair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority, Overmountain Recovery, Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee |
|
Troy Moore, PharmD, MS, BCPP |
|
Erika Titus-Lay, PharmD, BCPP, BCPS Assistant Professor California Northstate University College of Pharmacy Elk Grove, CA Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant |
2022 Reviewers
|
Audrey Abelleira, PharmD, BCPP, BCPS |
|
David Dadiomov, PharmD, BCPP |
|
James J. Gasper, PharmD, BCPP |
|
Cindy A. Gutierrez, PharmD, MS, BCPP |
|
Dara L. Johnson, PharmD, BCPP, BCACP |
|
Benjamin Miskle, PharmD |
|
Marnie Noel, PharmD, BCPP |
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: antidepressants, antipsychotics, benzodiazepines, buprenorphine, gabapentin, n-acetylcysteine, naltrexone, nicotine replacement therapy, oxytocin.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.